Get the Stockscreener App
1.20
2.56%
0.03
After Hours:
1.18
-0.02
-1.67%
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
NRx Pharmaceuticals submits NDA for intravenous ketamine drug - Mugglehead
Mira Pharmaceuticals expands pain management pipeline By Investing.com - Investing.com Australia
Mira Pharmaceuticals Develops Topical Formulation of Ketamir-2 for Pain Relief -March 13, 2025 at 09:30 am EDT - Marketscreener.com
Mira Pharmaceuticals succesfully develops topical version of its therapy for localized neuropathic and inflammatory pain - Marketscreener.com
Mira Pharmaceuticals expands pain management pipeline - Investing.com India
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain - Weatherford Democrat
Revolutionary Topical Pain Treatment: MIRA's Ketamir-2 Targets Multiple Pain Conditions - StockTitan
EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate - Benzinga
What is Zacks Small Cap’s Forecast for MIRA FY2024 Earnings? - Defense World
Mira Pharmaceuticals begins phase 1 trial for pain treatment By Investing.com - Investing.com Australia
SponsoredImpartialComprehensive - Research Tree
Urgent Boots paracetamol recall after packets found to contain a different drug - AOL
Mira Pharmaceuticals Announces Approval And Initiation Of Phase 1 Clinical Trial For Ketamir-2 In Neuropathic Pain - Marketscreener.com
Mira Pharmaceuticals begins phase 1 trial for pain treatment - Investing.com
Mira Pharmaceuticals announces approval, initiation of Phase 1 Ketamir-2 trial - TipRanks
MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain - accessnewswire.com
Can This Novel Ketamine Analog Outperform Gabapentin? MIRA's Neuropathic Pain Drug Enters Clinical Trials - StockTitan
EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain - Benzinga India
Tiziana stock jumps 12% on TBI drug study publication - MSN
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - AOL
Mira Murati's new AI startup poaches 20 OpenAI researchers - Reuters
MediPharm Labs terminates proposed sale of Napanee facility to Kensana Health - Seeking Alpha
Microstrategy Inc. – 8% PRF PERPETUAL USD 100 – Ser A’s (STRK) Stock: A Week-by-Week Analysis - The News Heater
Monday.Com Ltd (MNDY) Shares Down Despite Recent Market Volatility - The News Heater
Mira Pharmaceuticals Inc (MIRA) Stock: Evaluating the Market Performance - The News Heater
Vanda Pharmaceuticals Inc (VNDA) Shares Rise Despite Market Challenges - The News Heater
Air Transport Services Group Inc (ATSG) Stock: Evaluating the Market Performance - The News Heater
Report: OpenAI's ex-CTO, Mira Murati, has recruited OpenAI co-founder John Schulman - Yahoo Finance
OpenAI cofounder John Schulman is joining Mira Murati’s startup after brief stint at Anthropic - Yahoo Finance
Kernel and Mira Launch Industry’s First $300M Secured AI API - GlobeNewswire Inc.
Mira Network Launches $10M Grant Program for AI Builders - EIN News
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy? - AOL
UCalgary researchers to validate Mira Hormone Monitor - Yahoo Finance
TEVA Stock Drops Over 5% Amid Financial Struggles - GuruFocus.com
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End - ACCESS Newswire
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA - ACCESS Newswire
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.18% - MSN
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study - ACCESS Newswire
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance - ACCESS Newswire
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 - ACCESS Newswire
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development - ACCESS Newswire
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain - ACCESS Newswire
Wealth Enhancement Advisory Services LLC Acquires 6,454 Shares of PPL Co. (NYSE:PPL) - Defense World
International Assets Investment Management LLC Invests $29,000 in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World
MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Down 1.7% – Should You Sell? - Defense World
AMRN Stock Rises Over 5% Amidst Lack of Institutional Ratings - GuruFocus.com
Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation - Yahoo Finance
Cocrystal stock plunges 40% on influenza drug update (COCP:NASDAQ) - Seeking Alpha
Traws stock plunges 43% on financing update (TRAW:NASDAQ) - Seeking Alpha
Zacks Small Cap Has Pessimistic Outlook of MIRA Q4 Earnings - Defense World
Mira Pharmaceuticals appoints new accounting firm By Investing.com - Investing.com South Africa
Mira Pharmaceuticals appoints new accounting firm - Investing.com
Why Wall Street Expects This Growth Stock To Soar 99% In 2025 - Barchart
StatementProposed Amendments To The Air Passenger Protection Regulations - Barchart
Should You Buy Joby Aviation Stock While It's Below $10? - Barchart
C3.ai Stock: Buy, Sell, Or Steer Clear? - Barchart
Is Xcel Energy Stock Underperforming The Nasdaq? - Barchart
2 Fantastic Beaten-Down Growth Stocks Down 35% And 21% To Buy - Barchart
Missed Out on Nvidia: 1 No-Brainer Artificial Intelligence (AI) Stock to Buy Before It Crushes the Market in 2025, and Beyond - Barchart
2.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):